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https://doi.org/10.1016/j.stemcr.2019.04.014SUMMARYOrganotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with
immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically chal-
lenging. Here, we demonstrate the development and conduction of an organotypic HT Cl/I exchange assay using cystic fibrosis (CF)
disease-specific iPSCs. The introduction of a halide-sensitive YFP variant enabled automated quantitative measurement of Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) function in iPSC-derived intestinal epithelia. CFTR function was partially rescued by
treatment with VX-770 and VX-809, and seamless gene correction of the p.Phe508del mutation resulted in full restoration of CFTR func-
tion. The identification of a series of validated primary hits that improve the function of p.Phe508del CFTR from a library of 42,500
chemical compounds demonstrates that the advantages of complex iPSC-derived culture systems for diseasemodeling can also be utilized
for drug screening in a true HT format.INTRODUCTION
Patient-specific induced pluripotent stem cells (iPSCs) are
considered a valuable tool to model various types of dis-
eases, in particular based on genetic defects. Moreover, it
is presumed that iPSC technology, in combinationwith tar-
geted gene editing technologies, will open a new era in
drug development and testing (Ebert et al., 2012; Merkert
and Martin, 2018). The development of high-throughput
(HT) assays for drug screening, however, is considerably
exacerbated by the need for much larger cell numbers,
robust differentiation protocols, and the requirement for
automated and reliable readout systems. It is therefore
not surprising that as yet not many successful iPSC-based
screens have been conducted in drug development in a
true HT format (Shi et al., 2017).
Despite these apparent challenges, such screens have
important advantages compared with primary cells and
immortalized cell lines. These include (1) the possibility
of collecting patient-specific source cells, (2) the unlimited
potential for propagation, (3) the option to generate
different cell lineages from one patient-derived cell source,
(4) the possibility for targeted genome engineering on aStem Cell R
This is an open access article under the Cclonal level, (5) the existence of a cell lineage-specific
normal intracellular signal cascade, regulation, and proteo-
stasis environment, and (6) the possibility to integrate the
influence of genetic modifiers that play an important role
in the clinical manifestation of a disease. Overall, it is ex-
pected that iPSC-based phenotypic screening approaches
will result in higher success rates of compounds than
from conventional target-based screens (Vincent et al.,
2015).
In the case of cystic fibrosis (CF), recent HT screens have
identified modulators of the Cystic Fibrosis Transmem-
brane Conductance Regulator (CFTR), a chloride channel
expressed in secretory epithelia (Galietta, 2013). These
can be classified as CFTR potentiators, which restore the
channel activity by enhancing gating, and correctors,
which are able to rescue trafficking of specific mutants to
the cell surface in vitro, including the most common
CFTR mutant (p.Phe508del). By applying immortalized
cell lines, the CFTR potentiator VX-770 and the CFTR cor-
rectors VX-661 and VX-809 were identified. VX-770 was
reported to increase chloride secretion about 10-fold in pri-
mary human bronchial epithelial (HBE) cells heterozygous
for the gating mutation p.Gly551Asp (Van Goor et al.,eports j Vol. 12 j 1389–1403 j June 11, 2019 j ª 2019 The Authors. 1389
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Generation of CFTRdTomato Reporter iPSCs and Differentiation into Intestinal Epithelia
(A and B) PCA analysis. Global comparison of different hiPSC lines (healthy donor 1 [MHHi001-A, non-edited, shown in black], donor 2
[MHHi002-A-derived cell lines; CF parental line shown in green and seamless corrected line shown in blue], healthy donor 6 [MHHi006-A-
derived line, genetically edited, shown in gray]) by PCA show a clear clustering of the two isogenic lines based on donor 2 and more
(legend continued on next page)
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2009), wherebyVX-809was able to enhance chloride secre-
tion in HBE cells from homozygous p.Phe508del patients
to 14% of wild-type activity in vitro (Van Goor et al.,
2011). Results from clinical trials of VX-809 on homozy-
gous patients, however, were modest at best (Clancy
et al., 2012). Even with the combination of the potentiator
VX-770 and the corrector VX-809 for homozygous
p.Phe508del, CF patients showed an improvement in
lung function to a relatively low extent (Graeber et al.,
2018; Wainwright et al., 2015). The new triple combina-
tion of CFTR modulators (VX-661, VX-659, VX-770) so
far promises considerably more effect (Davies et al., 2018)
but needs further evaluation.
It is therefore clear that previous in vitro models for cor-
rectors are poor predictors of clinical efficacy, although
the most promising compounds were even validated on
primary human epithelial cells. This underlines the need
for the identification of novel compounds with a screening
system that closely recapitulates the in vivo situation and
the complexity of CF disease more accurately and reliable.
With patient-derived iPSCs, a suitable source of expandable
CF patient-derived cells is now available that can be genet-
ically engineered to establish appropriate reporter cell lines
and can be differentiated toward differentCFTR-expressing
derivatives of the most affected organs, including lung
(Huang et al., 2015), bile duct (Dianat et al., 2014), and in-
testinal epithelia (McCracken et al., 2011).
Here, we show that intestinal epithelia differentiated
from genetically engineered CF patient-derived iPSCs and
their isogenic control cells after seamless correction of the
p.Phe508del mutation can be utilized in an HT drug
screening approach. Screening of 42,500 chemical com-
pounds resulted in the identification of a number of
validated primary hits that showed rescue ofCFTR function
to a different extent, underlining that even complex func-
tional organotypic screens based on disease-specific iPSCdivergence from the two other hiPSC lines (donor 1 and donor 6), both
differentiation (B). n = 3 independent differentiations for each line.
(C) Schematic illustration of the targeting strategy applied for TAL
cassette. The CFTR gene is targeted at exon 1 in-frame with the ATG
integration of the reporter construct. NeoR, neomycin resistance gene;
dsRed fluorescent protein coupled to nuclear membrane location signa
promoter; HygroR, hygromycin resistance gene.
(D) Schematic illustration of the protocol for iPSC differentiation tow
as monolayer were induced to DE via the STEMdiff Definitive Endode
intestinal specification was promoted using BMP4, CHIR, and FGF10.
(E) Representative fluorescence microscopy showing emerging dTomat
of CFTRKO/Tom cells toward epithelial cells. BF, bright field. Scale bars
(F) Quantification of dTomatonuc-positive cells on day 15 of directed
intestinal epithelial cells (mean ± SEM from three independent differ
(G) Fold change of dTomatonuc and CFTR expression during the time cou
lines (mean ± SEM from three independent differentiations). The kno
Kozak sequence, which will result in mRNA transcription but not in Cderivatives can be conducted in a true HT format. Further
comprehensive analyses are now required to investigate
the degree of CFTR rescue in primary airway cells to iden-
tify binding sites and to elucidate mechanisms of action
of the individual compounds.RESULTS
Requirement for an Isogeneic Control Cell Line with
Seamless Correction of the p.Phe508del Mutation
Isogenic iPSC control lines with seamless correction of the
respective disease-specific mutation are generally consid-
ered as ultimate control in iPSC-based disease modeling.
Gene editing of iPSCs and the subsequent clonal selection
procedure, however, may not only lead to introduction of
new mutations but also to the selection of cell clones
with (epi)genetic aberrations that show altered culture
characteristics and differentiation behavior. In order to
confirm the similarity of the CFTR p.Phe508del line
MHHi002-A and its seamless corrected counterpart
MHHi002-A-1 (Merkert et al., 2017) to be used in our
screen, we have compared the global gene expression of
both cell lines before and after intestinal differentiation
(Figure 1). Principal component analysis (PCA) revealed
close clustering of the CFTR p.Phe508del line (donor 2
derived) with its isogenic gene-corrected counterpart, but
more divergence from two unrelated human iPSC lines
(donor 1 and donor 6 derived), either in the undifferenti-
ated state (Figure 1A) or after intestinal differentiation (Fig-
ure 1B). This indicates, that despite gene editing and the
single-cell cloning procedure, the seamless corrected sub-
clone is still much more similar to the parental cell line
than other unrelated iPSC lines, all generated in the same
laboratory. This was confirmed by a more detailed compar-
ison of differentially expressed genes (DEGs) between thein the undifferentiated state on day 0 (A) and on day 15 of directed
For further analyses, also see Figure S1.
EN-mediated integration of the neomycin-2A-dTomatonuc reporter
start codon. Gray arrows indicate primers used to confirm targeted
T2A, self-cleaving peptide sequence; dTomatonuc, dimeric variant of
l; frt, flippase recognition target site; PGK, phosphoglycerate kinase
ard CFTRdTomato-expressing intestinal epithelial cells. iPSCs cultured
rm Kit. Following the application of dorsomorphin and IWP-2, the
onuc-positive cells during the time course of directed differentiation
represent 100 mm.
differentiation of four CFTR-dTomatonuc reporter iPSC lines toward
entiations).
rse of directed differentiation of four CFTR-dTomatonuc reporter iPSC
ckout allele in the CFTRKO/Tom line was generated via deletion of the
FTR protein translation (see also Figure S1E).
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Table 1. Overview of Generated Reporter iPSC Lines
Name Parental Line CFTR Genotypea CFTR Phenotype Abbreviation
MHHi006-A-1 (CFTRdTomato74)b MHHi006-A wild type functional CFTRwt/Tom
MHHi006-A-3 (CFTRKO/CFTRdTomato89)b,c MHHi006-A knockout no protein CFTRKO/Tom
MHHi002-A-3 (CFTRdTomato4)d MHHi002-A p.Phe508del mutated CFTRp.Phe508del/Tom
MHHi002-A-2 (CFTRdTomato2)d,e MHHi002-A-1 corrected p.Phe508del functional CFTRcorr/Tom
All cell lines are targeted monoallelic with the dTomatonuc reporter in the CFTR locus.
aGenotype of the non-targeted CFTR allele.
bZeocin-dTomatonuc reporter.
cMissing Kozak sequence (initiates translation process) upstream of the ATG start codon of one CFTR allele results in monoallelic CFTR knockout (for details
see Figure S1E).
dNeomycin-dTomatonuc reporter.
eBased on MHHi002-A, which was heterozygously corrected with ssODNs (Merkert et al., 2017).applied cell lines, which resulted in higher numbers of
DEGs for the comparison of unrelated cell lines, either
genetically engineered (donor 6 derived) or not further
engineered (donor 1), in contrast to the comparison of
the mutation-corrected subclone and its parental cell line
(Figures S1A and S1B).
Generation of Human CFTRdTomato Reporter iPSC
Lines
Efficiency and reliability of differentiation protocols are a
critical prerequisite for application of iPSC-derived cells
on an industrial scale, including HT drug screens. In order
to enable straightforward monitoring of CFTR-expressing
cells on a single-cell level during the differentiation of
iPSCs, we placed a dTomato-fluorescent protein coupled
to a nuclear membrane localization signal (dTomatonuc)
under the control of the CFTR locus of a CF_p.Phe508del
iPSC line (MHHi002-A) and its heterozygously corrected
counterpart (MHHi002-A-1) (Figures 1C, S1C, and S1D).
Allele-specific PCR analysis confirmed dTomatonuc integra-
tion into the p.Phe508del mutated allele of the heterozy-
gously corrected CF iPSC line (data not shown). For all
further procedures and analyses, one correctly targeted
clone each was selected from the CF iPSCs and the muta-
tion-corrected iPSCs. In addition, two previously estab-
lished CFTR wild type and knockout control cell lines
carrying a zeocin resistance instead of the neomycin
resistance were applied. For clarity, all selected reporter
cell lines that were applied for analysis hereafter are abbre-
viated according to their CFTR genotype: CFTRwt/Tom,
CFTRKO/Tom, CFTRp.Phe508del/Tom, and CFTRcorr/Tom as listed
in Table 1.
Differentiation of CFTRdTomato Reporter iPSC Lines
Considering the very complex, costly, and time-
consuming culture protocols for differentiation into airway
cells, we decided to develop an HTassay based on CFTR-ex-1392 Stem Cell Reports j Vol. 12 j 1389–1403 j June 11, 2019pressing intestinal epithelia, which can be generated using
a much shorter and less costly protocol. For the generation
ofCFTR-expressing intestinal epithelia, a stepwise differen-
tiation protocol via definitive endoderm (DE) and posterior
endodermwas developed (Figure 1D, for details see Supple-
mental Information). All cell lines were capable of gener-
ating DE as shown by CXCR4/C-KIT and CXCR4/EPCAM
co-staining on day 4 of differentiation (Figures S1F and
S1G), although with slightly less efficiency in the case of
the CFTRp.Phe508del/Tom and CFTRcorr/Tom cell lines. CFTR-
dTomatonuc-positive cells emerged around day 8 during
the time course of differentiation. After 15 days, the cul-
tures showed distinct CFTR-dTomatonuc-expressing cells
with clear fluorescence localization restricted to the cell
nuclei (Figure 1E). Microscopic quantification of the
dTomatonuc signal on day 15 of differentiation resulted in
an average of 58% and 45% positive cells for the
CFTRKO/Tom and CFTRwt/Tom cell clones and 17% and 6%
for the CFTRp.Phe508del/Tom and CFTRcorr/Tom clone, respec-
tively (Figure 1F). dTomatonuc mRNA expression started to
increase from day 8 of differentiation, which reflected the
kinetics of the CFTR mRNA expression (Figure 1G) and
the appearance of the red fluorescence in the differentia-
tion cultures.
Detailed Characterization of the Intestinal Epithelial
Cell Population
Microarray expression analysis of the resulting cell popula-
tions on day 15 of differentiation and tissue controls
(intestine and liver) were conducted. PCA revealed a clear
separation of differentiated (d15) hiPSCs from their undif-
ferentiated (d0) counterparts and adult liver but close clus-
tering with adult intestine (Figure 2A). More detailed
comparative expression analyses were conducted for all
genes with >2-fold elevated expression (p > 0.01) in differ-
entiated (d15) versus undifferentiated iPSCs (d0) and in
intestine versus undifferentiated (d0) iPSCs (Table S3). In
total, 4,045 genes were significantly upregulated in the d15
differentiation samples compared with undifferentiated
(d0) iPSC samples; 5,018 genes were detected with signifi-
cantly elevated expression in adult intestinal tissue with
its diverse cellular components compared with d0 cells
(Table S3). Comparative analysis of both gene lists resulted
in an intersection of 2,094 genes (Table S3), which were
significantly upregulated in both groups, accounting for
about 51% of the upregulated genes in the differentiated
cells (Figure 2B). Detailed analysis of the genes with
elevated expression showed enrichment of GO terms con-
nected to intestinal absorption (GO 0098865, 0030299),
immunity (GO 0002446, 0043312), brush border mem-
brane (GO 0031526), and epithelial cell differentiation
(GO0030855) (Figure S2A) (Chen et al., 2013; Kuleshov
et al., 2016). Furthermore, differentiated cells and intestine
showed a shared expression pattern indicated by the
expression levels of selected individual genes involved in
digestive tract development, intestinal cell differentia-
tion/development, and genes expressed in the mature in-
testine (e.g., SI, VIL1, LCT, ALPI) (Figure 2C). Markers
connected to the development such as GATA5, GATA6,
CCBR, FGFR3, and EGFR were also elevated in the differen-
tiated population, suggesting that the iPSC-derived intesti-
nal cells did not adopt a fully mature adult phenotype. In
addition, a gene list (Table S4) compiled of GO term lists
connected to intestine development and function as well
as gene lists from the human protein atlas for intestine
and colon (https://www.proteinatlas.org) was used to
further compare expression profiles of undifferentiated
cells (d0), differentiated cells (d15), and intestine. The
generated heatmap of upregulated genes underlines the in-
testinal-like expression pattern of the differentiated cells
(Figure 2D).
Differentiated CFTR-expressing epithelial cells were
dissociated on day 15 of differentiation and seeded at
high density on membrane inserts for functional an-
alyses. When re-seeding the cells on Laminin-511-coated
inserts, low cuboidal morphology and also ZO-1 expres-
sion, indicating intact tight junctions, could be observed
(Figure S2B), which consistently (n = 3) resulted
in higher transepithelial electrical resistance (TEER) than
collagen I/fibronectin or Geltrex coating (data not
shown). Four days after seeding, TEER reached on average
1,130 U cm2 in CFTR corrected cells and 1,070 U cm2 in
the mutated cells (Figure S2C). Apical surface liquid (ASL)
height measurements were performed to assess the transe-
pithelial fluid transport capacity of the differentiated cells
on the filters. While no response to Forskolin could
be observed in CFTR mutated cells (Figure S2D), the addi-
tion of Forskolin increased theCFTR-dependent fluid trans-
port activity in corrected cells at a rate of approximately
12 mm/h, indicating that the iPSC-derived cell populationexpresses all required apical and basolateral transport sys-
tems in addition to the apical chloride channel CFTR.
Generation of Halide-Sensitive eYFP Reporter iPSC
Lines and Measurement of CFTR Channel Activity in
iPSC-Derived Intestinal Epithelia in aCl/I Exchange
Assay
For the development of an iPSC-based automatable func-
tional screening approach, a halide-sensitive eYFP (HS-
eYFP) reporter (Figures 3A and 3B) was integrated into the
AAVS1 locus (Figures 3C and S3A) of the four CFTRdTomato
iPSC lines listed in Table 1, enabling functional analysis
of the endogenous CFTR channel. All established reporter
iPSC lines exhibited a bright HS-eYFP fluorescence signal
and retained the hallmarks of pluripotent stem cells, and
stable transgene expression was observed in cell types of
all three germ layers (Figures 3D, S3B, and S3C).
The four established AAVS1eYFP/CFTRdTomato iPS reporter
cell lines were differentiated toward CFTR-dTomatonuc-ex-
pressing intestinal epithelial cells. After 15 days, the cul-
tures developed distinct dTomatonuc-positive cells with
clear fluorescence localization at the cell nuclei and co-
expression of HS-eYFP (Figure 3E). The differentiated cells
were analyzed for CFTR activity in a microscopic Cl/I ex-
change assay (Galietta et al., 2001b) (Figure 3F). In the
preparation of a plate reader-based HT screening with our
differentiated reporter cells, we included a 24 h pre-incuba-
tion step for putative correctors in DMSO (Figure 3F). The
whole-cell batch analysis of the HS-eYFP intensity changes
revealed comparable results with the analysis of individual
dTomatonuc-positive cells (Figure S3D). Therefore, we
continued analyzing the HS-eYFP fluorescence changes as
batch analyses of the entire differentiated cell population.
Forskolin stimulation of CFTRwt/Tom and CFTRcorr/Tom cells
resulted in a significant reduction of the HS-eYFP fluores-
cence after the addition of iodide, which was absent in
CFTRKO/Tom as well as in CFTRp.Phe508del/Tom cells (Figure 3G,
left graph). To verify the specificity of the CFTR-mediated
HS-eYFP reduction, the CFTR channel was specifically in-
hibited via CFTR(inh)-172, a thiazolidinone-class inhibitor
acting as closed-channel stabilizer. CFTR(inh)-172 has been
used as a selective inhibitor to identify CFTR currents in
various cell types (Ma et al., 2002a; Thiagarajah et al.,
2004). This resulted in a considerable reduction of halide
transport in CFTRwt/Tom and CFTRcorr/Tom cells in compari-
son with Forskolin stimulation only (Figure 3G, right
graph). All recorded traces were summarized via calculation
of the maximal slope after iodide addition and statistically
analyzed (Figure 3H). We obtained significant differences
for CFTR activation with and without CFTR(inh)-172
treatment in differentiated CFTRwt/Tom as well as in
CFTRcorr/Tom cells. Furthermore, a significant difference in
halide transport was detected between differentiatedStem Cell Reports j Vol. 12 j 1389–1403 j June 11, 2019 1393
Figure 2. Human iPSC-Derived Epithelial Cells Share Expression Patterns with Adult Intestine
(A) PCA was conducted on undifferentiated hiPSCs (d0) (n = 11, independent biological samples), differentiated hiPSC (d15) (n = 12,
independent biological samples), adult intestine (n = 3, technical replicates), and adult liver (n = 3, technical replicates). Differentiated
hiPSCs (d15) cluster with adult intestine (in red) but are distinct from undifferentiated hiPSCs (d0) and adult liver (in cyan).
(legend continued on next page)
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mutantCFTRp.Phe508del/Tom cells and the differentiated gene-
corrected CFTRcorr/Tom cells. Forskolin stimulation of undif-
ferentiated reporter iPSCs and DMSO vehicle control of
differentiated reporter iPSCs did not lead to any reduction
of the HS-eYFP signal after addition of iodide (Figures S3E
and S3F).
Development and Conduction of an HT Screening
Assay
In order to use our functional iPSC-based assay for HT drug
screening, the iPSC-derived CFTR-expressing intestinal
epithelial cells were dissociated on day 13 of differentiation
and re-plated into a 384-well format using a device micro-
plate dispenser. A seeding density of 10,000 cells/well was
chosen to ensure the formation of a tight epithelial layer.
The re-plated cells re-adhered, spread, and formed tight
junctions as demonstrated on day 15 of differentiation,
the time point of the Cl/I exchange assay, via immuno-
fluorescence staining. The tight junction marker protein
ZO-1 and the expression of fetal intestinal markers such
as AFP, CDX2, and SOX9 could be confirmed, as well as
the co-expression of the HS-eYFP (Figure S4A).
The HS-eYFP fluorescence changes of CFTRcorr/Tom and
CFTRp.Phe508del/Tom cells were acquired using a fully auto-
mated fluorescent image plate reader (FLIPRTM) and re-
vealed a significant reduction of the HS-eYFP signal in the
gene-corrected CFTRcorr/Tom cells, which was absent in the
mutant CFTRp.Phe508del/Tom cells (Figures 4A and 4B). We
further evaluated the effect of the approved CFTR corrector
VX-809 to rescue the halide transport in differentiated
mutant CFTR cells in combination with the potentiator
VX-770 and two other correctors, VX-661 and corr-4a (Pe-
demonte et al., 2005). VX-809 and/or VX-661 or corr-4a
were added 24 h prior to Forskolin activation at different
concentrations at lower temperature of 28C (Pedemonte
et al., 2005; Van Goor et al., 2011). VX-770 was added al-
ways at a constant concentration of 1 mM in parallel to For-
skolin. Treatment of cells with 0.2 mMand 10 mMVX-809 at
28C led to significantly reduced HS-eYFP fluorescence
compared with the control (Figure 4B). The combination
of VX-809 and VX-661 showed no further improvement
of the CFTR function compared with VX-809 alone. An(B) A Venn diagram was created from gene lists containing genes w
cultures compared with d0 cultures (yellow, 4,045 genes) and in adu
intersection of both gene lists contains 2,094 genes.
(C) Relative expression levels of selected individual genes connected
tract development, biliary/hepatic cells (and also intestinal develop
entiated iPSCs (d0; n = 11), differentiated iPSCs (d15; n = 12), and a
(D) A heatmap of upregulated genes in differentiated cells (d15) an
based on a gene list compiled of GO terms connected to intestine deve
listed in the human protein atlas for intestine and colon (https://www
are more similar to adult intestine than to undifferentiated cells (d0additive effect could be observed for the combination of
VX-809 and corr-4a, which resulted in the highest
p.Phe508del activity (Figures 4A and 4B).
We performed a primary HT screen of 42,500 com-
pounds from the FMP compound library of the chemical
biology platform (Lisurek et al., 2010) at a single concentra-
tion of 10 mM. The whole screening workflow (Figure 4C)
comprising cell seeding on day 13 of differentiation, me-
dium exchange, and compound transfer on day 14, as
well as theCl/I exchange assay on day 15, was performed
in an automated manner. This enabled the handling of up
to 26 384-well plates per differentiation batch leading
to the accomplishment of the whole library after five
screening rounds. The quality of the differentiated cell
batches was assessed by day 4 flow cytometry analyses for
DE formation and day 13 qPCR analysis for CFTR and
CDX2 expression (Figures S4B and S4C). We calculated
the slopes from the FLIPRTM kinetic curves using R software
and evaluated the performance of our assay based on the
range between positive (corrected cells) and negative con-
trols (mutated cells). We assessed the assay quality using
in-house software, applying Z0 factor and Z score calcula-
tions for each screening plate. Generated graphics enabled
visualization of the statistical value distribution over plate
and edge effects (Figure 4D). The Z0 factor, which represents
the assay response window, was 0.55, supporting the feasi-
bility and reproducibility of the screening (Figure 4E). Po-
tential hits were identified by determination of the relative
activity of the compounds in comparisonwith themutated
(value 0) and the genetically corrected cells (value 1). After
fixation and staining of cell nuclei, automated image anal-
ysis for determination of cell numbers/well was applied to
detect the potential toxicity of individual compounds (Fig-
ure 4F). After primary screening, we identified 86 hit com-
pounds with a relative activity >0.38 (Figure 5A). For these
compounds, a validation run was performed, whereby 11
concentrations from20 mMto 0.02 mMwere tested in dupli-
cates. All 86 tested compounds were ranked according to
their relative activity compared with the hit cutoff of 0.38
as well as by visual confirmation of the kinetic curves.
This resulted in preselection of 21 verified hits (Figure 5B).
Among those, seven compounds reached the relativeith R2-fold elevated expression (p > 0.01) in d15 differentiation
lt intestine compared with d0 cultures (green, 5,018 genes). The
to intestinal epithelial cell differentiation/development, digestive
ment), as well as brush border enzymes/cytoskeleton in undiffer-
dult intestine (n = 3).
d intestine compared with undifferentiated cells (d0) was created
lopment and function (http://www.geneontology.org/) and genes
.proteinatlas.org/), further demonstrating that differentiated cells
).
Stem Cell Reports j Vol. 12 j 1389–1403 j June 11, 2019 1395
Figure 3. Generation of Human Halide-Sensitive AAVS1eYFP/CFTRdTomato Reporter iPSC Lines that Express Functional CFTR after
Directed Differentiation into Intestinal Epithelia
(A) Binding of iodide to the HS-eYFP protein results in a reduced fluorescence intensity.
(B) Simplified schematic representation of the chloride/iodide exchange assay to analyze CFTR function. CFTR channel stimulation via
Forskolin allows iodide influx into the cell leading to decreased HS-eYFP fluorescence intensity.
(legend continued on next page)
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activity hit cutoff at a concentration of 10 mM, nine com-
pounds at 20 mM, and five compounds were included as
borderline compounds although they showed less activity
at both concentrations (Figures 5C, S5A, and S5B). Among
those 21, we selected our ten most promising compounds
(Figures S5C and S5D) as the top candidates for prioritized
testing for chemical structure clustering as well as further
investigation in secondary assays.DISCUSSION
To capture the pathophysiology of a disease, the applica-
tion of organotypic iPSC-based models that incorporate
the genomic background in connection with the corre-
sponding clinical phenotypes already in the earliest
in vitro assaysmay result in better clinical translation (Engle
and Vincent, 2014; Swinney and Anthony, 2011). Since ge-
netic modifiers play an important role in the clinical mani-
festation of CF (Tu¨mmler and Stanke, 2014), we did not
consider unrelated wild-type iPSCs as proper control for
the patient-derived CFTRp.Phe508del/Tom cells, but applied
isogenic corrected cells generated by targeted gene editing
for the HT screen.While it has been shown that the genetic
background contributes to the CF phenotype, it has not
been investigated in detail whether mutations and epige-
netic differences unintentionally acquired during targeted
gene editing or selected during the single-cell cloning pro-
cedure may also cause functional alterations relevant for
disease modeling and drug screening. We therefore consid-
ered it important to explore the degree of similarity be-
tween the two cell lines used in the HT screen, the
CFTRp.Phe508del/Tom iPSC line and the disease corrected coun-
terpart CFTRcorr/Tom, including their differentiated progeny.
Remarkably, ourmicroarray analysis underlines the general
significance of isogenic control cell lines. Despite various
steps of genetic engineering and single-cell cloning, both
undifferentiated and differentiated derivatives of the seam-(C) Schematic illustration of the AAVS1 targeting strategy. The don
flanked by two arms of AAVS1 locus homology sequences. Gray arrow
gration of the reporter construct. CAG, cytomegalovirus early enhanc
F46L, halide-sensitive enhanced yellow fluorescent protein.
(D) Microscopic images of a transgenic AAVS1eYFP iPSC clone on feede
(E) Representative live imaging of AAVS1eYFP/CFTRdTomato reporter cells
(F) Timeline of cell seeding, cell preparation, and chloride/iodide
with VX-809 or vehicle containing culture medium 1 day after re-s
Forskolin ± 20 mM CFTR(inh)-172 ± 1 mM VX-770. Subsequently, HS-
137 mM sodium iodide was added after 30 s.
(G) Representative traces of HS-eYFP fluorescence changes for all fo
indicate iodide addition. Cells were either stimulated with 20 mM Fors
prior to addition of iodide.
(H) Statistical analysis of the maximal slopes of the fluorescence chang
lines (n = 9–11 traces from at least three independent differentiationless corrected subclone (applied as positive control in our
HT screen) cluster much closer to their mutated parental
counterparts in terms of DEGs than two unrelated CFTR
wild-type iPSC lines with different genetic background.
Since robust and reliable differentiation protocols are a
basic requirement for iPSC-based HT screens, we sought
to eliminate sources of interference wherever possible. In
order to achieve a robust intestinal differentiation, we al-
ways started from iPSCmonolayers cultured under defined
conditions. Moreover, a commercial endoderm differentia-
tion kit, which in our hands yielded the most reproducible
results, and, as far as possible, smallmolecules instead of re-
combinant proteins were applied to further increase the
reliability of the differentiation protocol. During subse-
quent differentiation, intestinal marker genes, including
CDX2, SI, andVIL1, were significantly upregulated. In addi-
tion, we also found upregulation of genes frequently
considered as hepatic and biliary genes (e.g., AFP, HNF4a,
KRT19, KRT7). This might be prevented by addition of
FGF4, which was shown to suppress the formation of he-
patic gene expression at the hindgut stage (Tamminen
et al., 2015). The hepatic and biliary markers detected,
however, are also known to be expressed on intestinal cells
during development (Cirillo et al., 1995; Stammberger and
Baczako, 1999; Tsai et al., 2017; Verzi et al., 2013). Since on
the other hand some marker genes for mature secretory
epithelia cells (e.g., MUC2, CHGA) are not expressed in
our intestinal cell population, we conclude that our intesti-
nal cell population does not show a fully mature adult
phenotype.
The use of iPSC lines that express a dTomatonuc fluoro-
chrome under control of one allele of the CFTR locus
enabled visualization of CFTR-expressing cells during
intestinal differentiation. Because of the lack of reliable
anti CFTR antibodies for the detection of relatively low
physiological protein expression levels (Kalin et al., 1999;
Mendes et al., 2004), we refrained from co-staining of our
dTomatonuc-expressing cells with any CFTR antibodies.or vector contains an eYFP-H148Q-I152L-F46L expression cassette
s represent primers used for PCR analysis to confirm targeted inte-
er element coupled to chicken b-actin promoter; eYFP-H148Q-I152-
r cells. Scale bars represent 100 mm.
on day 15 of directed differentiation. Scale bars represent 100 mm.
exchange assay. If required, cells were pre-incubated for 24 h
eeding. For the HS-eYFP assay, cells were incubated with 20 mM
eYFP fluorescence was microscopically recorded for 120 s, whereby
ur reporter cell lines on day 15 of directed differentiation. Arrows
kolin (left) or with 20 mM CFTR(inh)-172 + 20 mM Forskolin (right)
es obtained frommicroscopic HS-eYFP assay for all four reporter cell
s; black lines show the mean).
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Figure 4. Development of an Automated Assay for High-Throughput Measurement of CFTR Function in iPSC-Derived Epithelial Cells
(A) Representative FLIPRTM HS-eYFP fluorescence kinetic data of differentiated CFTRcorr/Tom cells (blue) and CFTRp.Phe508del/Tom cells (green)
in 384-well format. Arrow indicates iodide addition. Dotted line represents CFTRp.Phe508del/Tom cells pre-incubated with 10 mM VX-809 and
5 mM corr-4a for 24 h. All wells were pre-incubated at 28C and treated with 1 mM VX-770 (each trace represents three wells).
(B) Statistical analysis of the slopes from the FLIPRTM kinetic curves, after 24 h CFTR rescue, via treatment with VX-809, corr-4a, or VX-661,
as indicated. Cells were incubated at 28C, stimulated with 20 mM Forskolin, and in all experiments the potentiator VX-770 was applied at
1 mM (n = 48 wells; black lines show the mean). CFTRKO/Tom cells are depicted in orange, CFTRcorr/Tom cells are depicted in blue,
CFTRp.Phe508del/Tom cells are depicted in green.
(C) Schematic workflow of the 3-day screening procedure, starting from day 13 of differentiation with the plating of the cells in 384-well
format until automated HS-eYFP assay at day 15 of differentiation.
(D) Heatmap of a representative screening plate, displaying the median of the statistic value as gradient color (10 MAD, median, +10
MAD). The last two columns contain the control samples. MAD, median absolute deviation.
(E) The calculation of the Z0 factor demonstrates the signal window of the HT assay. Z’standard value calculation was performed based on the
maximal slope from the FLIPR kinetic curves. The plot represents representative data of 48 replicate wells across a 384-well plate of both
(legend continued on next page)
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Figure 5. High-Throughput Screening of the FMP Library Identifies Chemical Modulators of CFTR Function
(A) Scatterplot graph of potential hits from the primary screen at 10 mM. Depicted are all compounds (triangles) resulting in relative
activity >0.38 (dotted line), which are considered hits. The library was distributed over 121 384-well plates; each plate contains 8 positive
control wells (represented by a blue line), 8 negative control wells (represented by a green line), 8 control wells with p.Phe805del cells
incubated with VX-809 and corr-4a (exemplarily shown as green dots), and 8 CFTR knockout wells (data not shown). All plates were
incubated for 24 h at 28C; 1 mM VX-770 was added for 45 min before HS-eYFP assay performance.
(B) Overview of screening steps with filters for compound selection.
(C) Scatterplot graph of EC50 validation at 10 mM as the mean (n = 2 independent plates). Depicted are all 86 potential hits from the primary
screen. Compounds confirming relative activity above hit cutoff at 10 mM are depicted in red, at 20 mM in dark red, and borderline
compounds in orange.Nevertheless, since the kinetics of CFTR-dTomatonuc
mRNA expression correspond to the appearance of
dTomatonuc-positive cells during differentiation, and
because the CFTR mRNA expression detected could be
functionally confirmed in our HS-eYFP assay, there is no
reason to doubt the specificity of the dTomatonuc reporter,negative (mutated cells in green) and positive (genetically corrected c
and subsequently removed from the positive replicate data. Gray sol
3-fold SD (s).
(F) Cell distribution of a representative 384-well screening plate mon
Counted nuclei analysis was used for exclusion of toxic compounds.which is placed under control of the endogenous CFTR
locus.
It is noteworthy that both reporter lines derived from
MHHi006-A reproducibly showed a substantially higher
proportion of CFTR-dTomatonuc-expressing cells than the
MHHi002-A derived lines. In addition, we observedells in blue) controls. Three data points were determined as outliers
id lines represent the mean (m), dotted lines represent respective
itored by automated microscopy of Hoechst 33342 stained nuclei.
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differences in terms of the formation of CFTR-dTomatonuc-
expressing cells also between the genetically engineered
subclones of MHHi006-A, and between subclones of
MHHi002-A. Already the efficiency of endoderm differenti-
ation was line dependent with both MHHi006-A lines
reproducibly yielding about 90% pure DE under the given
conditions. These differences were accompanied by clear
differences in the proliferation rates of the four lines during
culture expansion and further differentiation. The differing
proliferation rates of the four lines very likely explain at
least in part the different amounts of CFTR-positive cells,
and may be adjustable by individualized timing of the
differentiation protocol for each line. The observed
different proliferation and differentiation characteristics
underline the impact of the genetic background and clonal
variations.
In addition to the availability of functional iPSC deriva-
tives that allow mimicking the disease in a dish, another
critical requirement for iPSC-based HTscreens is the poten-
tial for automation. For measurement of CFTR function
in vitro, in particular the use of a halide-sensitive eYFP re-
porter, is straightforward and can be automated due to its
simplicity and sensitivity (Ma et al., 2002b). The respective
HS-eYFP (Galietta et al., 2001a), however, has so far been
applied only for functional measurement of CFTR trans-
genes overexpressed in immortalized cell lines (Ma et al.,
2002b; Park et al., 2016) but not to analyze more moderate
levels of endogenousCFTR in primary epithelia or stem cell
derivatives. Here, we demonstrate that the halide-sensitive
eYFP-H148Q-I152L-F46L variant facilitates measurement
of endogenous CFTR function in iPSC-derived epithelia.
While a normal CFTR response was detected in CFTRwt/Tom
cells, no significant decrease in the HS-eYFP fluorescence
could be observed in the CFTRKO/Tom cells.
Remarkably, the seamless correction of the CFTR
p.Phe508del mutation in the CFTRcorr/Tom cell line perfectly
restored CFTR function to wild-type levels in our micro-
scope-based HS-eYFP assay as well as in the plate reader
setting. Furthermore, the CFTR function detected in
CFTRwt/Tom and CFTRcorr/Tom cells could be blocked by
CFTR(inh)-172. Similar to other studies in which CFTR
overexpressing cell lines were applied (Caci et al., 2008;
Fischer et al., 2010; Ma et al., 2002a), we did not observe
full inhibition of the CFTR channel activity, which might
be an effect of the interior negative membrane potential
of epithelial cells reducing the CFTR(inh)-172 potency.
Interestingly, we observed comparable levels of CFTR func-
tion in intestinal epithelia derived from the MHHi006-A
CFTR wild type and the genetically corrected MHHi002-
A-1 iPSC line, although the proportion of CFTR-
dTomatonuc-expressing cells in the respective differentia-
tion cultures was quite divergent (6% versus 45%; see also
discussion above). Actually, probably two effects may1400 Stem Cell Reports j Vol. 12 j 1389–1403 j June 11, 2019contribute to this phenomenon: (1) dTomatopos cells
within the cell population represent those cells that show
high levels of CFTR expression, while other cells that do
not show a detectable dTomato expression may express
lower but still substantial levels of CFTR, and (2) CFTR-
dTomatopos and CFTR-dTomatoneg cells couple via gap
junctions that propagate the halide influx to neighboring
cells (Bjerknes et al., 1985; Gumber et al., 2014).
As proof of concept for the usefulness of our iPSC-based
assay in drug development, we analyzed the approved
CFTR drug combination Orkambi (CFTR corrector VX-
809 and CFTR potentiator VX-770) to rescue the CFTR
p.Phe508del in iPSC-derived intestinal epithelia. Pre-incu-
bation of CFTRp.Phe508del/Tom with VX-809 and VX-770 at
28C led to 5-fold increased CFTR function, demonstrated
by HS-eYFP decrease. The additional application of corr-4a
even increased the CFTR function up to 17-fold. This
represents almost 50% CFTR function compared with the
gene-corrected control. Comparable studies applying the
HS-eYFP assay with CFTR p.Phe508del overexpressing
immortalized cell lines, reached up to 25% CFTR function
after pre-incubation with VX-809 at 37C (Favia et al.,
2014; Vijftigschild et al., 2013). Also the application of
VX-809 and VX-770 in p.Phe508del human bronchial
epithelial cells resulted in a CFTR-mediated chloride trans-
port that reached levels equivalent to approximately 25%
of that measured in non-CF HBE (Van Goor et al., 2011).
Although 28C pre-incubation does not reflect physiolog-
ical conditions, we chose 28C pre-incubation to increase
the likelihood for the identification of evenweakCFTR cor-
rectors (Pedemonte et al., 2005), which might be useful for
drug combination strategies and still bear the potential for
improvement after structural optimization.
Finally, we adapted our assay to the 384-well HT plate
reader format and conducted an HT screen for potential
CFTR modulators in a fully automated screening environ-
ment. Intestinal epithelia cells instead of airway cells
were chosen for the HT assay because of the shorter, more
reproducible, and less cost-intensive differentiation proto-
col. Further validation of compounds and testing of com-
pound combinations can be performed in secondary assays
on different disease-relevant cell types derived from the
same CF reporter iPSC lines, as well as on primary airway
cells or intestinal organoids from other patients.
In conclusion, our study underlines the feasibility of HT
screens based on iPSC-derived epithelia for identification of
potentiators and correctors of mutated CFTR. Clonal
genome engineering approaches can be utilized in iPSCs
to integrate fluorescence reporters that enable visualization
of CFTR expression during differentiation and facilitate
automated measurement of CFTR function at an HT scale.
In contrast to p.Phe508del CFTR overexpressing immortal-
ized cell lines, iPSC-based screens incorporate the influence
of the proteostasis environment on CF disease and the effi-
cacy of correctors. Our approach, based on cells with a
more physiological array of proteins involved in protein
folding, quality control, degradation, and trafficking, and
with more physiological levels of CFTR expression, will
favor the development of correctors with novel mecha-
nisms of action, more relevant to the therapeutic goal
in vivo. Forthcoming HT screens will show whether such
iPSC-based organotypic assays are better predictors of clin-
ical compound efficacy than conventional HT screens.EXPERIMENTAL PROCEDURES
Fordetaileddescription seeSupplemental ExperimentalProcedures.
Cell Culture
We used the HSC_F1285_T-iPS2 (Hartung et al., 2013) cell line,
registered (https://hpscreg.eu/) as MHHi006-A, the CF iPSC line
MHHi002-A and its corrected counterpart MHHi002-A-1 (Merkert
et al., 2017), all generated in our research group. Unless indicated
otherwise, all pluripotent stem cell lines were cultured under stan-
dard conditions essentially as previously described (Merkert et al.,
2014).
TALEN-Based Targeted Gene Editing
For the integration of the reporter constructs, iPSCs grown as
monolayer cultures were dissociated and transfected with the
respective TALEN expression and donor plasmids. Cells were
seeded either onto hygromycin-resistant feeder cells for CFTR tar-
geting or on Geltrex coated culture vessels for AAVS1 targeting.
For the generation of CFTRdTomato reporter cell lines, the hygromy-
cin-based clone selection was initiated 72 h post transfection for
4 days. Arising colonies were transferred manually onto irradiated
feeder cells to generate single-cell clones. For the generation of
AAVS1eYFP reporter cell lines, eYFPpos cells were sorted via fluores-
cence-activated cell sorting and plated in limiting dilution. Up-
coming colonies were picked manually and expanded clonally.
iPSC Differentiation
In a stepwise differentiation protocol, iPSCs from monolayers in
essential 8 (E8) medium were first differentiated to DE via a
STEMdiff Definitive Endoderm Kit (TeSR-E8 Optimized) from
STEMCELL Technologies. DE cells on day 4 of differentiation
were cultured for 2 days in the presence of dorsomorphin and
ROCK inhibitor. Thereafter, cells were treated for 1 day with
IWP-2. From day 7 until day 15, cells were cultured in the presence
of CHIR99021, BMP4, and FGF10.
Microscope-Based Chloride/Iodide Exchange Assay
Cells on day 13 of differentiation and undifferentiated cells serving
as controls were seeded on glass-bottom dishes (Figure 3F). On day
15, individual cell or batch analysis of eYFP fluorescence intensity
after addition of sodium iodide was performed microscopically at
37C. Cells werewashed oncewith PBS and incubatedwith Forsko-
lin, Forskolin + CFTR(inh)-172, or respective DMSO control,
respectively. eYFP fluorescence was recorded continuously for120 s with one picture per second. Thirty seconds after the start
of recording, iodide-rich PBS was added and the fluorescence in-
tensity was measured for another 90 s. Negative values reflect a
decrease of eYFP fluorescence intensity.
Plate Reader-Based Chloride/Iodide Exchange Assay
Cells were dissociated on day 13 of differentiation and seeded on
black 384-well plates. The next day, the compounds were applied
in differentiationmedium and incubated for 24 h at 28C. To start
the assay, the cells were washed three times with PBS and incu-
bated for 45–50 min at room temperature with 20 mM Forskolin +
1 mM VX-770. The eYFP fluorescence intensity was analyzed for
120 s with 1 read/s in an FLIPR Tetra system. After 30 s, the 2.75-
fold volume of iodide-rich PBS was automatically added, and the
change in eYFP fluorescence intensity further monitored. After-
ward, the cells were fixed with paraformaldehyde and stained
with Hoechst 33342 for automated cell counting.
Statistics
Statistical analyses were performed with GraphPad Prism6 and the
results are presented as means ± SEM, unless otherwise noted. Sig-
nificance of two groups was analyzed using the unpaired t test. Sta-
tistical significance was assigned as follows: *p% 0.05; **p% 0.01;
***p% 0.001; ****p% 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2019.04.014.
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